Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject : An observational, cross-sectional survey to evaluate the management of patients with Allergic Rhinitis with nasal congestion and role of Fluticasone Oxymetazoline Fixed Dose Combination Nasal spray

Allergic rhinitis (AR)occurs when an allergen is the trigger for the nasal symptoms. NAR is when obstruction and rhinorrhoea occur in relation to nonallergic, non-infectious triggers such as change in the weather, exposure to caustic doors or cigarette smoke, barometric pressure differences, etc.

Both are highly prevalent diseases that have a significant economic burden on society and negative impact on patient quality of life.

The prevalence of AR has been reported from 10% to 40 % worldwide. AR is primarily driven by an immunoglobulin E (IgE)-mediated type 1 hypersensitivity response, due to an allergen exposure.

Classic AR symptoms include sneezing, rhinorrhoea, and nasal congestion/obstruction. These symptoms are non-specific, and the differential diagnosis of AR is broad.

For phenotype classification, various criteria may be used, including the severity of disease (mild, moderate/severe), pattern of symptoms (seasonal/perennial or intermittent/persistent), predominant symptom (runners/blockers), possible triggering factor (allergens, infectious agents, etc.) and response to treatment (controlled/uncontrolled). The typical profile of patients with AR includes mostly young women, non-smokers with moderate/severe rhinitis, with persistent/perennial clinical behaviour, and with conjunctivitis and asthma.

AR has been associated with both increased risk of asthma development and asthma severity. The exact mechanisms underlying these relationships have yet to be fully elucidated, but evidence supports a role for allergen sensitization. Compared to those with asthma alone, patients with comorbid AR and asthma have greater use of health care resources, including visits to the general practitioner, emergency department and hospitalizations.

Asthma is a complex multifactorial disease and has a significant impact on quality of life. The patient presents with respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, which vary over time and in severity. Globally, the estimated burden of asthma in India is 34.3 million patients, accounting for 13.09% of the global population. In India, 13.2 per thousand deaths occur due to asthma compared to the global asthma burden, India has a three times higher death rate.

There is limited real-world Indian data available on the management of patients with Allergic Rhinitis with nasal congestion and role of Fluticasone Oxymetazoline Fixed Dose Combination Nasal spray. There are various treatment modalities like oral tablets, inhalers, nasal sprays available in different drug classes. This multicentric survey is designed to evaluate the management of patients with Allergic Rhinitis with nasal congestion and role of Fluticasone Oxymetazoline Fixed Dose Combination Nasal spray in an Indian Setting.